Relieved of ‘high-risk’ marker, New Horizon Health aims to break even next year
Encouraged by its fast-growing revenue last year, the cancer screening device maker believes its losses may end in 2023 Key Takeaways: New Horizon Health is expected to attract more investors…
Recent Articles
RELATED ARTICLES
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK - Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
BRIEF: New Horizon Health announces chairman’s departure
6606.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
iMotion Automotive rides DeepSeek fever to new fundraising
1274.HK
